The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement ...

Regeneron Pharmaceuticals Inc. will offer a gene therapy that restored hearing for a small number of profoundly deaf children at no cost after US regulators approved the treatment.

Food and Drug Administration ‌has approved Regeneron's ‌gene therapy for a rare genetic ​form of deafness, the company said on Thursday. The company said the therapy will ‌be available ⁠for free to ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest company to agree to a new price policy push.

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

Regeneron Pharmaceuticals announced that the FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), a bispecific antibody treatment for adult patients with relapsed or refractory ...

President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative. China’s Xi ...